127 related articles for article (PubMed ID: 32371582)
1. A Qualitative Transcriptional Signature for Predicting Prognosis and Response to Bevacizumab in Metastatic Colorectal Cancer.
Yang J; Song K; Guo W; Zheng H; Fu Y; You T; Wang K; Qi L; Zhao W; Guo Z
Mol Cancer Ther; 2020 Jul; 19(7):1497-1505. PubMed ID: 32371582
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis.
Cao D; Zheng Y; Xu H; Ge W; Xu X
Sci Rep; 2019 Dec; 9(1):20326. PubMed ID: 31889159
[TBL] [Abstract][Full Text] [Related]
3. Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.
Zuurbier L; Rahman A; Cordes M; Scheick J; Wong TJ; Rustenburg F; Joseph JC; Dynoodt P; Casey R; Drillenburg P; Gerhards M; Barat A; Klinger R; Fender B; O'Connor DP; Betge J; Ebert MP; Gaiser T; Prehn JHM; Griffioen AW; van Grieken NCT; Ylstra B; Byrne AT; van der Flier LG; Gallagher WM; Postel R
Oncotarget; 2017 Jun; 8(26):42949-42961. PubMed ID: 28487489
[TBL] [Abstract][Full Text] [Related]
4. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
[TBL] [Abstract][Full Text] [Related]
5.
Papachristos A; Kemos P; Katsila T; Panoilia E; Patrinos GP; Kalofonos H; Sivolapenko GB
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752122
[TBL] [Abstract][Full Text] [Related]
6. Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer.
Zhou Q; Perakis SO; Ulz P; Mohan S; Riedl JM; Talakic E; Lax S; Tötsch M; Hoefler G; Bauernhofer T; Pichler M; Gerger A; Geigl JB; Heitzer E; Speicher MR
Genome Med; 2020 Feb; 12(1):20. PubMed ID: 32087735
[TBL] [Abstract][Full Text] [Related]
7. Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer.
Makondi PT; Lee CH; Huang CY; Chu CM; Chang YJ; Wei PL
PLoS One; 2018; 13(1):e0189582. PubMed ID: 29342159
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
Matsusaka S; Hanna DL; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Okazaki S; Berger MD; Miyamato Y; Parekh A; Stintzing S; Loupakis F; Lenz HJ
Clin Cancer Res; 2016 Jul; 22(13):3218-26. PubMed ID: 26839145
[TBL] [Abstract][Full Text] [Related]
9. A qualitative transcriptional signature for determining the grade of colorectal adenocarcinoma.
Zheng H; Song K; Fu Y; You T; Yang J; Guo W; Wang K; Jin L; Gu Y; Qi L; Zhao W; Guo Z
Cancer Gene Ther; 2020 Sep; 27(9):680-690. PubMed ID: 31595030
[TBL] [Abstract][Full Text] [Related]
10. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab treatment in metastatic colorectal carcinoma - an economic perspective.
Sehnalová I; Říhová B; Demlová R
Ceska Slov Farm; 2019; 68(2):43-47. PubMed ID: 31331174
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of First-Line Bevacizumab in Metastatic Colorectal Cancer: The Observational Cohort Study GRETA.
Franchi M; Barni S; Tagliabue G; Ricci P; Mazzucco W; Tumino R; Caputo A; Corrao G;
Oncologist; 2019 Mar; 24(3):358-365. PubMed ID: 30097524
[TBL] [Abstract][Full Text] [Related]
13. Individualized predictive signatures for 5-fluorouracil-based chemotherapy in right- and left-sided colon cancer.
Song K; Zhao W; Wang W; Zhang N; Wang K; Chang Z
Cancer Sci; 2018 Jun; 109(6):1939-1948. PubMed ID: 29700901
[TBL] [Abstract][Full Text] [Related]
14. Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy.
Ulivi P; Scarpi E; Chiadini E; Marisi G; Valgiusti M; Capelli L; Casadei Gardini A; Monti M; Ruscelli S; Frassineti GL; Calistri D; Amadori D; Passardi A
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28598398
[TBL] [Abstract][Full Text] [Related]
15. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
16. Patients with low nicotinamide N-methyltransferase expression benefit significantly from bevacizumab treatment in ovarian cancer.
Li J; Yue H; Yu H; Lu X; Xue X
BMC Cancer; 2021 Jan; 21(1):67. PubMed ID: 33446144
[TBL] [Abstract][Full Text] [Related]
17. Association of antibiotic exposure with the mortality in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy: A hospital-based retrospective cohort study.
Lu L; Zhuang T; Shao E; Liu Y; He H; Shu Z; Huang Y; Yao Y; Lin S; Lin S; Chen X; Chen X
PLoS One; 2019; 14(9):e0221964. PubMed ID: 31504043
[TBL] [Abstract][Full Text] [Related]
18. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
Hanna DL; Loupakis F; Yang D; Cremolini C; Schirripa M; Li M; Matsusaka S; Berger MD; Miyamoto Y; Zhang W; Ning Y; Antoniotti C; Salvatore L; Moran M; Zeger G; Astrow SH; Falcone A; Lenz HJ
Clin Colorectal Cancer; 2018 Sep; 17(3):e471-e488. PubMed ID: 29636300
[TBL] [Abstract][Full Text] [Related]
20. Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer.
Ito M; Kusaba H; Mukaide S; Kishimoto J; Shimokawa H; Tamura S; Makiyama A; Hirano G; Oda H; Shirakawa T; Komoda M; Uchino K; Tanaka R; Mitsugi K; Esaki T; Arita S; Ariyama H; Akashi K; Baba E
Anticancer Drugs; 2017 Nov; 28(10):1166-1173. PubMed ID: 28906258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
